Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax

Published: Jan 17, 2013

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 2 clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. NuThrax, a next generation vaccine being developed as part of Emergent's anthrax franchise, consists of Anthrax Vaccine Adsorbed in combination with a novel immunostimulatory adjuvant, CPG 7909.

Back to news